Matches in SemOpenAlex for { <https://semopenalex.org/work/W2599550248> ?p ?o ?g. }
Showing items 1 to 51 of
51
with 100 items per page.
- W2599550248 abstract "BACKGROUNDAromatase inhibitor (AI) therapy results in substantial survival benefits for patients with hormone receptor-positive breast cancer. The rates of poor adherence and discontinuation of AI therapy are high, primarily because of treatment-related toxicities like musculoskeletal pain. Although pain-related symptoms may worsen during AI therapy, the authors hypothesized that nonpersistence with AI therapy was associated with symptoms that were present before treatment initiation.METHODSPostmenopausal women initiating AI therapy who were enrolled in a prospective clinical trial completed questionnaires at baseline to assess sleep, fatigue, mood, and pain. Reasons for treatment discontinuation during the first year of treatment were recorded. Associations between baseline patient-reported symptoms and treatment discontinuation because of toxicity were identified using logistic regression.RESULTSFour hundred forty-nine patients were evaluable. The odds of treatment discontinuation were higher in patients who reported a greater number of symptoms before AI initiation. Baseline poor sleep quality was associated with early treatment discontinuation, with an odds ratio (OR) of 1.91 (95% confidence interval [CI], 1.26-2.89; P = .002). Baseline presence of tired feeling and forgetfulness had similar ORs for discontinuation (tired feeling: OR, 1.76; 95% CI, 1.15-2.67; P = .009; forgetfulness: OR, 1.66; 95% CI, 1.11-2.48; P = .015). An increasing total number of baseline symptoms was associated with an increased likelihood of treatment discontinuation, with an OR of 1.89 (95% CI, 1.20-2.96; P = .006) for 3 to 5 symptoms versus 0 to 2 symptoms.CONCLUSIONSSymptom clusters in breast cancer survivors that are present before the initiation of adjuvant AI therapy may have a negative impact on a patient's persistence with therapy. Interventions to manage these symptoms may improve breast cancer outcomes and quality of life. Cancer 2014;120:2403–2411. © 2014 American Cancer Society." @default.
- W2599550248 created "2017-04-07" @default.
- W2599550248 creator A5003434684 @default.
- W2599550248 creator A5012387907 @default.
- W2599550248 creator A5034119300 @default.
- W2599550248 creator A5040793701 @default.
- W2599550248 creator A5053390874 @default.
- W2599550248 creator A5056530735 @default.
- W2599550248 creator A5062446153 @default.
- W2599550248 creator A5069582641 @default.
- W2599550248 creator A5069748055 @default.
- W2599550248 creator A5083487516 @default.
- W2599550248 date "2014-08-15" @default.
- W2599550248 modified "2023-09-27" @default.
- W2599550248 title "Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy" @default.
- W2599550248 hasPublicationYear "2014" @default.
- W2599550248 type Work @default.
- W2599550248 sameAs 2599550248 @default.
- W2599550248 citedByCount "0" @default.
- W2599550248 crossrefType "journal-article" @default.
- W2599550248 hasAuthorship W2599550248A5003434684 @default.
- W2599550248 hasAuthorship W2599550248A5012387907 @default.
- W2599550248 hasAuthorship W2599550248A5034119300 @default.
- W2599550248 hasAuthorship W2599550248A5040793701 @default.
- W2599550248 hasAuthorship W2599550248A5053390874 @default.
- W2599550248 hasAuthorship W2599550248A5056530735 @default.
- W2599550248 hasAuthorship W2599550248A5062446153 @default.
- W2599550248 hasAuthorship W2599550248A5069582641 @default.
- W2599550248 hasAuthorship W2599550248A5069748055 @default.
- W2599550248 hasAuthorship W2599550248A5083487516 @default.
- W2599550248 hasConcept C121608353 @default.
- W2599550248 hasConcept C126322002 @default.
- W2599550248 hasConcept C156957248 @default.
- W2599550248 hasConcept C2776166826 @default.
- W2599550248 hasConcept C2778504769 @default.
- W2599550248 hasConcept C2778715236 @default.
- W2599550248 hasConcept C530470458 @default.
- W2599550248 hasConcept C71924100 @default.
- W2599550248 hasConceptScore W2599550248C121608353 @default.
- W2599550248 hasConceptScore W2599550248C126322002 @default.
- W2599550248 hasConceptScore W2599550248C156957248 @default.
- W2599550248 hasConceptScore W2599550248C2776166826 @default.
- W2599550248 hasConceptScore W2599550248C2778504769 @default.
- W2599550248 hasConceptScore W2599550248C2778715236 @default.
- W2599550248 hasConceptScore W2599550248C530470458 @default.
- W2599550248 hasConceptScore W2599550248C71924100 @default.
- W2599550248 hasOpenAccess W2599550248 @default.
- W2599550248 isParatext "false" @default.
- W2599550248 isRetracted "false" @default.
- W2599550248 magId "2599550248" @default.
- W2599550248 workType "article" @default.